Related Experiment Video
Updated: Apr 28, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Adoptive Cell Therapies for Glioblastoma: A Quest for Cures from Within
Jia-Shiun Leu1, Xin Ge1, Charles Robin Yu2
1Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Abstract:
Glioblastomas (GBMs) are the most aggressive form of brain cancer recalcitrant to both current standard-of-care and immune checkpoint therapies that benefit other cancer patients. Adoptive cell therapies (ACT) using patients' own immune cells have long been explored as a treatment strategy, including the historically studied lymphokine-activated killer (LAK) cells, the evolving chimeric antigen receptor (CAR) directed immune cells, the newly emerging tumor-infiltrating T lymphocyte (TIL) therapies, and others. Preclinical and clinical studies have shown promise but also highlighted significant challenges. In this review, we summarize these findings, highlight recent developments, discuss current limitations, and emphasize how ACT may benefit from contemporary and future insights into the co-evolution of TILs with other cells within the GBM tumor microenvironment (TME).
Insights
Adoptive cell therapies (ACT) show promise for treating aggressive glioblastomas (GBMs). Further research into the tumor microenvironment (TME) is crucial for overcoming challenges and improving ACT efficacy in brain cancer treatment.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Biology
Background:
- Glioblastomas (GBMs) are aggressive brain tumors resistant to current treatments, including immune checkpoint therapies.
- Adoptive cell therapies (ACT), utilizing patient immune cells, are being explored as an alternative treatment strategy.
- Existing ACT approaches include lymphokine-activated killer (LAK) cells, chimeric antigen receptor (CAR) T cells, and tumor-infiltrating lymphocyte (TIL) therapies.
Purpose of the Study:
- To review the current landscape of ACT for glioblastomas.
- To summarize preclinical and clinical findings, highlighting both promise and challenges.
- To discuss how insights into the glioblastoma tumor microenvironment (TME) can advance ACT.
Main Methods:
- Literature review of preclinical and clinical studies on ACT for GBM.
- Analysis of different ACT modalities (LAK, CAR, TIL).
- Examination of the interplay between immune cells and the GBM TME.
Main Results:
- ACT strategies have demonstrated potential in treating glioblastomas.
- Significant challenges remain in the clinical application of ACT for GBM.
- The GBM TME presents a complex barrier to effective immune cell function.
Conclusions:
- ACT offers a promising avenue for glioblastoma treatment, but challenges must be addressed.
- Understanding the co-evolution of TILs within the GBM TME is critical for optimizing ACT.
- Future advancements in ACT efficacy may stem from deeper insights into the tumor immune microenvironment.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
